Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site

Hitoshi Kusaba, Yoshihiro Shibata, Shuji Arita, Hiroshi Ariyama, Eishi Baba, Kenji Mitsugi, Mine Harada, Shuji Nakano

研究成果: Contribution to journalArticle

4 引用 (Scopus)

抜粋

A combination chemotherapy of 5-fluorouracil (5-FU) and cisplatin (CDDP) has demonstrated activities in various malignancies, including head and neck, lung, esophageal, gastric, and pancreatic cancers. We reviewed our experience of 11 patients diagnosed as carcinoma of unknown primary site (CUPS), who were treated with infusional 5-FU and CDDP between January 1998 and December 2005. The median number of cycles administered was three (range: 1-12). All patients had measurable disease. Six partial responses were obtained (response rate: 54.5%, 95% confidence interval: 23.4-83.3%). The median survival time for all patients was 10 mo (range, 2-37 mo). The median time to disease progression was 3 mo (range, 1-6 mo). This regimen was well tolerated, with grade 3-4 neutropenia (two patients), febrile neutropenia (one patient), grade 3 nausea/vomiting (one patient), and grade 3 stomatitis (two patients). Grade 2 leukoencephalopathy was observed in one patient. No treatment-related death was observed. The combination chemotherapy of infusional 5-FU and CDDP was feasible and tolerated with promising activity for CUPS.

元の言語英語
ページ(範囲)259-264
ページ数6
ジャーナルMedical Oncology
24
発行部数2
DOI
出版物ステータス出版済み - 6 1 2007

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

フィンガープリント Infusional 5-fluorouracil and cisplatin as first-line chemotherapy in patients with carcinoma of unknown primary site' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用